Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

NCT05599256 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Transplant-Related Disorder

Interventions

DRUG: Ruxolitinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China